Table 2.
Target volume dose parameters after transposition of breathhold plan (BH) to repeated breathhold (RBH) and failure to breathhold (FTBH) CT anatomy.
| ROI | BH | FTBH | RBH | ||||
|---|---|---|---|---|---|---|---|
| Dose (Gy) ± sd | Dose (Gy) ± sd | T-statistic | P-value | Dose (Gy) ± sd | T-statistic | P-value | |
| CTV WBI | |||||||
| Dmean | 40.42 ± 0.17 | 40.33 ± 0.21 | 3.045 | 0.007 | 40.47 ± 0.18 | − 0.508 | 0.617 |
| D02 | 42.59 ± 0.71 | 42.44 ± 0.74 | 2.435 | 0.025 | 42.63 ± 0.75 | − 1.496 | 0.151 |
| D50 | 40.42 ± 0.13 | 40.37 ± 0.18 | 1.935 | 0.068 | 40.45 ± 0.16 | − 1.461 | 0.160 |
| D95 | 38.76 ± 0.44 | 38.55 ± 0.44 | 4.394 | < 0.001 | 38.66 ± 0.49 | 2.293 | 0.033 |
| D98 | 38.00 ± 0.66 | 37.69 ± 0.70 | 3.219 | 0.005 | 37.90 ± 0.75 | 1.679 | 0.110 |
| LNN II | |||||||
| Dmean | 40.40 ± 0.44 | 40.26 ± 0.55 | 1.090 | 0.289 | 40.42 ± 0.36 | − 0.210 | 0.836 |
| D02 | 41.62 ± 0.85 | 41.81 ± 0.73 | − 1.475 | 0.156 | 41.70 ± 0.84 | − 1.096 | 0.287 |
| D50 | 40.40 ± 0.43 | 40.51 ± 0.38 | − 1.389 | 0.190 | 40.43 ± 0.38 | − 0.644 | 0.527 |
| D95 | 39.45 ± 0.33 | 38.06 ± 2.30 | 2.631 | 0.016 | 39.35 ± 0.39 | 0.846 | 0.408 |
| D98 | 39.09 ± 0.48 | 36.57 ± 3.36 | 3.372 | 0.003 | 38.90 ± 0.61 | 1.120 | 0.277 |
| LNN III | |||||||
| Dmean | 40.50 ± 0.53 | 40.49 ± 0.48 | 0.160 | 0.875 | 40.56 ± 0.65 | − 1.251 | 0.226 |
| D02 | 42.18 ± 0.98 | 42.24 ± 1.00 | − 0.478 | 0.638 | 42.38 ± 1.11 | − 2.963 | 0.008 |
| D50 | 40.48 ± 0.52 | 40.53 ± 0.45 | − 0.618 | 0.544 | 40.55 ± 0.61 | − 1.543 | 0.139 |
| D95 | 39.23 ± 0.45 | 38.98 ± 0.51 | 2.475 | 0.023 | 39.12 ± 0.86 | 1.056 | 0.304 |
| D98 | 38.66 ± 0.93 | 38.34 ± 0.81 | 1.494 | 0.152 | 38.41 ± 1.55 | 1.393 | 0.180 |
| LNN IV | |||||||
| Dmean | 40.44 ± 0.49 | 40.46 ± 0.96 | − 0.079 | 0.938 | 40.46 ± 0.68 | − 0.105 | 0.918 |
| D02 | 42.48 ± 0.98 | 43.01 ± 1.23 | − 2.401 | 0.027 | 42.64 ± 1.25 | − 0.882 | 0.389 |
| D50 | 40.48 ± 0.48 | 40.63 ± 0.69 | − 1.223 | 0.236 | 40.51 ± 0.69 | − 0.249 | 0.806 |
| D95 | 38.67 ± 1.16 | 37.77 ± 2.50 | 1.581 | 0.130 | 38.60 ± 1.17 | 0.444 | 0.661 |
| D98 | 37.51 ± 2.98 | 36.34 ± 3.50 | 1.365 | 0.188 | 37.54 ± 2.65 | 0.045 | 0.964 |
| LNN MI | |||||||
| Dmean | 40.67 ± 0.36 | 40.23 ± 1.23 | 1.772 | 0.092 | 40.46 ± 0.76 | 1.370 | 0.187 |
| D02 | 42.62 ± 0.82 | 43.37 ± 1.75 | − 1.988 | 0.061 | 42.58 ± 1.05 | 0.271 | 0.789 |
| D50 | 40.65 ± 0.38 | 40.55 ± 1.07 | 0.488 | 0.631 | 40.49 ± 0.76 | 1.144 | 0.267 |
| D95 | 39.14 ± 0.22 | 36.09 ± 4.25 | 3.200 | 0.007 | 38.69 ± 1.12 | 1.859 | 0.079 |
| D98 | 38.45 ± 0.47 | 33.90 ± 5.57 | 3.653 | 0.003 | 37.93 ± 1.63 | 1.528 | 0.143 |
| CTV LNN | |||||||
| Dmean | 40.44 ± 0.33 | 40.36 ± 0.47 | 0.678 | 0.506 | 40.47 ± 0.42 | − 0.525 | 0.605 |
| D02 | 42.33 ± 0.91 | 42.65 ± 0.96 | − 1.783 | 0.091 | 42.48 ± 1.04 | − 1.599 | 0.126 |
| D50 | 40.40 ± 0.27 | 40.50 ± 0.35 | − 1.172 | 0.256 | 40.46 ± 0.35 | − 1.010 | 0.325 |
| D95 | 39.16 ± 0.26 | 38.03 ± 1.69 | 2.863 | 0.010 | 38.97 ± 0.58 | 1.503 | 0.149 |
| D98 | 38.45 ± 0.93 | 36.44 ± 2.78 | 3.040 | 0.007 | 38.27 ± 1.09 | 0.954 | 0.352 |
| (LNN I) | |||||||
| Dmean | 20.08 ± 4.95 | 20.14 ± 5.15 | − 0.173 | 0.865 | 20.03 ± 4.98 | 0.910 | 0.374 |
| D02 | 40.66 ± 0.75 | 40.92 ± 0.78 | − 2.765 | 0.012 | 40.74 ± 0.81 | − 0.743 | 0.467 |
| D50 | 17.61 ± 7.93 | 17.80 ± 8.12 | − 0.620 | 00.543 | 17.46 ± 7.93 | 2.518 | 0.021 |
| D95 | 3.95 ± 4.02 | 3.82 ± 3.56 | 0.813 | 0.426 | 3.92 ± 3.94 | 1.008 | 0.326 |
| D98 | 3.08 ± 3.07 | 3.06 ± 2.86 | 0.150 | 0.882 | 3.07 ± 2.98 | 0.190 | 0.852 |
CTV LNN is what we consider the unoperated axilla, i.e. LNN II + LNN III + LNN IV but excluding CTV MI (a target volume with separate planning optimization). (LNN I): this region is not included as a target volume in our trial, but we report dose to this region for the interested reader. Tests report comparisons of either FTBH or RBH to BH.
CTV WBI clinical target volume of the treated breast, ROI region of interest, Dxx minimum dose received by xx% of ROI volume, LNN I through IV lymph node levels I–IV, LNN MI internal mammary nodes, Dmean mean dose delivered to ROI volume.